What is GSK3359609?
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody designed to selectively enhance T cell function, showed promising anti-tumour activity in combination with pembrolizumab in PD-1/L1 naive patients with head and neck squamous cell carcinoma (HNSCC) …
What is Feladilimab?
Feladilimab (formerly GSK 3359609) is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody, being developed by GlaxoSmithKline, for the treatment of solid tumours and haematological malignancies. The antibody targets and binds to ICOS expressed on tumour infiltrating CD4-positive T cells.
